Acute pain

Collegium Announces Publication of Real-World Data in Journal of Pain Research

Retrieved on: 
Wednesday, June 16, 2021
Psychoactive drugs, Pain, Branches of biology, Acute pain, Euphoriants, Morphinans, Nociception, Drug culture, Oxycodone, Pain management, Opioid, Oxymorphone

We will continue to support the analysis and publication of real-world data as it becomes available.

Key Points: 
  • We will continue to support the analysis and publication of real-world data as it becomes available.
  • The publication can be found here: link
    Collegium is a specialty pharmaceutical company committed to being the leader in responsible pain management.
  • Xtampza ER (oxycodone) is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
  • Assess each patients risk prior to prescribing Xtampza ER and monitor all patients regularly for the development of these behaviors or conditions.

Global Topical Oxygen Therapy Market Report 2021: Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2019-2029 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 16, 2021
Health, Other Health, Actuarial science, Medicine, Clinical medicine, Branches of biology, Necrosis, Acute pain, First aid, Injuries, Wound, Chronic wound, Compound annual growth rate, Annual growth rate

The "Topical Oxygen Therapy Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 to 2029" report has been added to ResearchAndMarkets.com's offering

Key Points: 
  • The "Topical Oxygen Therapy Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 to 2029" report has been added to ResearchAndMarkets.com's offering
    Topical oxygen therapy market is anticipated to grow at a CAGR of 3.5% during the forecast period from 2021 to 2029.
  • Compounded Annual Growth Rate (CAGR) for each segment is calculated for the forecast period from 2021 to 2029.
  • Factors driving this market include growing incidence of chronic wounds, increasing patient pool of diabetics, and high incidence of wound site infections.
  • Some of the major trends responsible for market growth are increased number of surgical procedures, and technological advancement in advanced wound care.

FDA Approves StrataGraft for the Treatment of Adults with Thermal Burns

Retrieved on: 
Tuesday, June 15, 2021
Medical specialties, Clinical medicine, Medicine, Acute pain, Medical emergencies, Plastic surgery, Skin grafting, Graft, Burn, Wound, Thermal burn, Artificial skin

For many deep burns, treatment frequently involves the removal of the damaged, burned skin and replacement with a skin graft.

Key Points: 
  • For many deep burns, treatment frequently involves the removal of the damaged, burned skin and replacement with a skin graft.
  • Treatment with StrataGraft can help avoid or decrease the amount of healthy skin that is needed for grafting.
  • The effectiveness and safety of StrataGraft are based on two randomized clinical studies involving a total of 101 adult patients with deep partialthickness thermal burns.
  • The effectiveness is demonstrated by the percentage of StrataGraft treatment sites that achieved a complete wound closure, and the significantly decreased need for autografts at the StrataGraft treatment sites.

Work-Injury Protocols Outdated; Fail to Include Orthopedists

Retrieved on: 
Tuesday, June 15, 2021
Medical specialties, Surgery, Clinical medicine, Traumatology, Acute pain, Medical emergencies, Surgical specialties, Orthopedic surgery, Arthroscopy, Major trauma, Injury

"It requires the patient to be seen in an occupational health center or general urgent care center where clinicians lack orthopedic expertise.

Key Points: 
  • "It requires the patient to be seen in an occupational health center or general urgent care center where clinicians lack orthopedic expertise.
  • But companies and insurers continue adhering to such a process because that is the way it has always been done."
  • This step is what delays return to work and dramatically increases cost and liability associated with a work injury.
  • Dr. Badia specializes in treating all problems related to the hand and upper extremities, including trauma, sports injury, joint reconstruction, nerve injuries and arthroscopic surgeries.

OliPass Expands Scientific Advisory Board by Inviting Experts in Pain To Bolster Phase 2 Clinical Trial Design and Management

Retrieved on: 
Thursday, June 10, 2021
Nervous system, Branches of biology, Symptoms and signs, Pain, Nociception, Acute pain, Neuropathic pain, Peripheral neuropathy

Professor Dougherty and Professor Dworkin will advise OliPass on Phase 2 clinical trials of OLP-1002.

Key Points: 
  • Professor Dougherty and Professor Dworkin will advise OliPass on Phase 2 clinical trials of OLP-1002.
  • Considering the pharmacological complexity of neuropathic pain, however, expertise in neuropathic pain and in clinical study design will be critical to a success in the clinical development of OLP-1002 against neuropathic pain.
  • We are very much honored to have Professor Dougherty and Professor Dworkin as new SAB members as we develop the first-in-class pain killer.
  • He has significantly contributed to defining mechanism of cancer therapy-induced pain and identifying potential therapeutic interventions for its relief or prevention.

RYAH Group, Inc Publishes Report on Medical Cannabis Use for Pain

Retrieved on: 
Thursday, June 10, 2021
Pain, Branches of biology, Medicine, Herbalism, Medicinal plants, Nociception, Acute pain, Palliative care, Medical cannabis, Cannabis, Chronic pain, Opioid

TORONTO, June 10, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- RYAH Group, Inc. (CSE:RYAH) (RYAH or the Company) is pleased to announce that its wholly owned subsidiary, RYAH Medtech Inc. ("RYAH Medtech"), has published a data report on use of medical cannabis among patients with pain conditions.

Key Points: 
  • TORONTO, June 10, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- RYAH Group, Inc. (CSE:RYAH) (RYAH or the Company) is pleased to announce that its wholly owned subsidiary, RYAH Medtech Inc. ("RYAH Medtech"), has published a data report on use of medical cannabis among patients with pain conditions.
  • The data report features insights into the use of cannabis to treat pain conditions by patients within the RYAH Data ecosystem and whether cannabis may be one of the alternative treatment solutions to reduce opioid use-related problems associated with existing treatment options.
  • The RYAH data report on cannabis use for pain management comes at a turning point as studies on alternatives to opioids in treatment and potential efficacy of chronic pain start to accelerate, says Gregory Wagner, CEO of RYAH.
  • RYAH Group, Inc. (RYAH) is a connected device and big data and technology company focused on valuable predictive analysis in the global medical plant and nutraceutical intake industry.

CyMedica Orthopedics Announces FDA Clearance for IntelliHab™, a Novel Drug-free, Non-invasive Modality for Treatment of Knee Osteoarthritis Pain

Retrieved on: 
Wednesday, June 9, 2021
Medical specialties, Clinical medicine, Medicine, Skeletal disorders, Rheumatology, Acute pain, Arthritis, Aging-associated diseases, Osteoarthritis, Pain management, Knee pain, Pain

With this clearance, IntelliHab is the only neuromodulation strengthening therapy indicated to treat pain associated with the debilitating osteoarthritis disease.

Key Points: 
  • With this clearance, IntelliHab is the only neuromodulation strengthening therapy indicated to treat pain associated with the debilitating osteoarthritis disease.
  • "CyMedica recognizes the current standard of care for managing knee osteoarthritis pain presents a significant gap in available treatment options," said Rob Morocco, President and Chief Executive Officer at CyMedica.
  • CyMedica Orthopedics has developed a therapy-based, pain management digital health platform designed to provide at-home pain relief for patients suffering from knee osteoarthritis.
  • Clinically proven to reduce knee pain associated with osteoarthritis and improve function, IntelliHab offers patients a non-invasive, non-opioid pain management solution.

NeuroMetrix Announces That Top-Line Results from a Randomized Controlled Trial of Quell® for Treatment of Fibromyalgia to be Presented at Two Upcoming Pain Medicine Conferences

Retrieved on: 
Wednesday, June 9, 2021
Pain, Branches of biology, Medicine, Pain management, Acute pain, Electrotherapy, Neurotechnology, Medical equipment, Transcutaneous electrical nerve stimulation, Quell, Fibromyalgia

WOBURN, Mass., June 09, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported that top-line results from a randomized controlled trial of Quell in patients with fibromyalgia will be presented at two upcoming pain medicine conferences.

Key Points: 
  • WOBURN, Mass., June 09, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported that top-line results from a randomized controlled trial of Quell in patients with fibromyalgia will be presented at two upcoming pain medicine conferences.
  • The double-blind, randomized, sham-controlled trial was conducted at the Center for Pain Management, Brigham and Women's Hospital (Boston, MA); ClinicalTrials.gov identifier NCT03714425 .
  • A poster titled "Outcome of TENS for Fibromyalgia: Randomized Sham-Controlled Trial" will be presented at the International Association for the Study of Pain (IASP) 2021 Virtual World Congress on Pain June 9-11 & 16-18.
  • Quell is a wearable neurostimulation device indicated for treatment of lower extremity chronic pain.

Orion’s Clinical Trial Shows Significant Improvement for Chronic Pain Patients Using Virtual Reality Therapy

Retrieved on: 
Wednesday, June 9, 2021
Pain, Medicine, Branches of biology, Nociception, Pain management, Health informatics, Acute pain, Pain scale, Chronic pain, Cognitive behavioral therapy, Promis, SAMD

Non-statistically significant improvements were reported with DTxP for Oswestry Disability Index (ODI), pain interference (Patient-Reported Outcomes Information System: PROMIS), and pain intensity (PROMIS-Numerical Rating Scale).

Key Points: 
  • Non-statistically significant improvements were reported with DTxP for Oswestry Disability Index (ODI), pain interference (Patient-Reported Outcomes Information System: PROMIS), and pain intensity (PROMIS-Numerical Rating Scale).
  • Cognitive Behavioral Therapy (CBT) is scientifically sound, effective and a recommended method to improve the self-management of chronic pain.
  • Orion is looking for a partner to further develop and commercialise Orions digital therapeutics software solution for Chronic Pain.
  • Orions DTxP, aimed to be a software as medical device (SaMD), is built for virtual reality (VR) devices to provide an immersive gamified therapeutic treatment program for the chronic pain patients.

New App Arms People with Strategies to Fight Chronic Pain, Live a Fuller Life

Retrieved on: 
Tuesday, June 8, 2021
Software, Text editors, Pain, Acute pain, Nociception, Pain management, Suffering, Vim, Chronic pain, Chronic condition

Named Vim , a word defined by "energy" and "enthusiasm," the app is a direct response to the chronic pain reported by patients in the Arthritis Foundation's ongoing Live Yes!

Key Points: 
  • Named Vim , a word defined by "energy" and "enthusiasm," the app is a direct response to the chronic pain reported by patients in the Arthritis Foundation's ongoing Live Yes!
  • Vim arms users with personalized pain management strategies and serves as a pocket-friendly way of tracking pain to help facilitate conversations with their doctor.
  • The all-in-one app is also a master motivator encouraging people to set attainable movement goals and rewarding them for their wins.
  • "Our research shows that chronic pain is pervasive affecting every aspect of a patient's life," said Taylor.